ARTELO BIOSCIENCES, INC. Investing Cash Flow
ARTELO BIOSCIENCES, INC. (ARTL) reported Investing Cash Flow of -$62.00 thousand for the 12-month period ending 2025-12-31, per its 8-K filed 2026-03-17.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-03-17
- ARTELO BIOSCIENCES, INC. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $188.00K, a 62.40% decline year-over-year.
- ARTELO BIOSCIENCES, INC. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was -$250.00K, a 105.88% decline year-over-year.
- ARTELO BIOSCIENCES, INC. net cash provided by (used in) investing activities for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- ARTELO BIOSCIENCES, INC. net cash provided by (used in) investing activities for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- ARTELO BIOSCIENCES, INC. net cash provided by (used in) investing activities for fiscal 2022 was $2.96M.
- ARTELO BIOSCIENCES, INC. net cash provided by (used in) investing activities for fiscal 2021 was -$3.44M.
- ARTELO BIOSCIENCES, INC. net cash provided by (used in) investing activities for fiscal 2020 was $0.00.
- ARTELO BIOSCIENCES, INC. net cash provided by (used in) investing activities for fiscal 2019 was -$1.50M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 4 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $188.00K derived: 8-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$62.00K derived: sum of 2 quarters · filed 2026-03-17 | -$62.00K derived: sum of 3 quarters · filed 2026-03-17 | -$62.00K 8-K · filed 2026-03-17 | |
| 2025-09-30 | -$250.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$250.00K derived: sum of 2 quarters · filed 2025-11-12 | -$250.00K 10-Q · filed 2025-11-12 | $250.00K derived: sum of 4 quarters · filed 2026-03-17 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 8-K 3 month · filed 2025-08-13 | $0.00 10-Q · filed 2025-08-13 | $500.00K derived: sum of 3 quarters · filed 2026-03-17 | $4.75M derived: sum of 4 quarters · filed 2026-03-17 | |
| 2025-03-31 | $0.00 8-K · filed 2025-07-11 | $500.00K derived: sum of 2 quarters · filed 2026-03-17 | $4.75M derived: sum of 3 quarters · filed 2026-03-17 | $6.50M derived: sum of 4 quarters · filed 2026-03-17 | |
| 2024-12-31 | $500.00K derived: 8-K 12 month − 10-Q 9 month · filed 2026-03-17 | $4.75M derived: sum of 2 quarters · filed 2026-03-17 | $6.50M derived: sum of 3 quarters · filed 2026-03-17 | $7.77M 8-K · filed 2026-03-17 | |
| 2024-09-30 | $4.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $6.00M derived: sum of 2 quarters · filed 2025-11-12 | $7.27M 10-Q · filed 2025-11-12 | $10.01M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | $1.75M derived: 10-Q 6 month − 8-K 3 month · filed 2025-08-13 | $3.02M 10-Q · filed 2025-08-13 | $5.76M derived: sum of 3 quarters · filed 2025-08-13 | $3.93M derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | $1.27M 8-K · filed 2025-07-11 | $4.01M derived: sum of 2 quarters · filed 2025-07-11 | $2.18M derived: sum of 3 quarters · filed 2025-07-11 | $2.58M derived: sum of 4 quarters · filed 2025-07-11 | |
| 2023-12-31 | $2.74M derived: 8-K 12 month − 10-Q 9 month · filed 2025-07-11 | $909.00K derived: sum of 2 quarters · filed 2025-07-11 | $1.31M derived: sum of 3 quarters · filed 2025-07-11 | $3.51M 8-K · filed 2025-07-11 | |
| 2023-09-30 | -$1.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$1.43M derived: sum of 2 quarters · filed 2024-11-12 | $766.00K 10-Q · filed 2024-11-12 | $2.56M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | $399.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $2.60M 10-Q · filed 2024-08-13 | $4.39M derived: sum of 3 quarters · filed 2024-08-13 | $1.31M derived: sum of 4 quarters · filed 2024-08-13 | |
| 2023-03-31 | $2.20M 10-Q · filed 2024-05-13 | $4.00M derived: sum of 2 quarters · filed 2024-05-13 | $915.00K derived: sum of 3 quarters · filed 2024-05-13 | $4.90M derived: sum of 4 quarters · filed 2024-05-13 | |
| 2022-12-31 | $1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | -$1.28M derived: sum of 2 quarters · filed 2024-03-25 | $2.70M derived: sum of 3 quarters · filed 2024-03-25 | $2.96M 10-K · filed 2024-03-25 | |
| 2022-09-30 | -$3.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $905.00K derived: sum of 2 quarters · filed 2023-11-13 | $1.16M 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | $3.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $4.24M 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | $257.00K 10-Q · filed 2023-05-11 | ||||
| 2021-12-31 | -$10.03M 10-K · filed 2023-03-31 | ||||
| 2021-11-30 | -$8.88M 10-Q · filed 2022-01-12 | ||||
| 2021-09-30 | $1.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $115.00K derived: sum of 2 quarters · filed 2022-11-08 | -$1.93M 10-Q · filed 2022-11-08 | ||
| 2021-08-31 | -$3.44M 10-K · filed 2023-03-31 | ||||
| 2021-06-30 | -$1.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$3.33M 10-Q · filed 2022-08-09 | |||
| 2021-03-31 | -$2.04M 10-Q · filed 2022-05-12 | ||||
| 2021-02-28 | -$510.69K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-04-13 | -$510.69K 10-Q · filed 2021-04-13 | -$509.52K derived: sum of 3 quarters · filed 2022-03-21 | -$509.52K derived: sum of 4 quarters · filed 2022-03-21 | |
| 2020-12-31 | -$1.05M 10-KT · filed 2022-03-21 | ||||
| 2020-11-30 | $0.00 10-Q · filed 2022-01-12 | $1.18K derived: sum of 2 quarters · filed 2022-03-21 | $1.18K derived: sum of 3 quarters · filed 2022-03-21 | ||
| 2020-08-31 | $1.18K derived: 10-KT 12 month − 10-Q 9 month · filed 2022-03-21 | $1.18K derived: sum of 2 quarters · filed 2022-03-21 | $0.00 10-KT · filed 2022-03-21 | ||
| 2020-05-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-07-12 | -$1.18K 10-Q · filed 2021-07-12 | |||
| 2020-02-29 | -$1.18K 10-Q · filed 2021-04-13 | ||||
| 2019-08-31 | -$1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2020-11-04 | -$1.50M 10-K · filed 2020-11-04 | |||
| 2019-05-31 | -$688.00 10-Q · filed 2020-07-13 | ||||
| 2018-08-31 | $42.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2019-12-18 | $42.00 derived: sum of 2 quarters · filed 2019-12-18 | $22.00 derived: sum of 3 quarters · filed 2019-12-18 | -$845.00 10-K/A · filed 2019-12-18 | |
| 2018-05-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-07-15 | -$20.00 derived: sum of 2 quarters · filed 2019-07-15 | -$887.00 10-Q · filed 2019-07-15 | ||
| 2018-02-28 | -$20.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-04-15 | -$887.00 10-Q · filed 2019-04-15 | |||
| 2017-11-30 | -$867.00 10-Q · filed 2019-01-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B |